U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Alnylam Pharmaceuticals

Market Cap: US$37.3b

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Insmed

Market Cap: US$23.8b

Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.

Summit Therapeutics

Market Cap: US$11.7b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Ionis Pharmaceuticals

Market Cap: US$9.0b

A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

Praxis Precision Medicines

Market Cap: US$8.9b

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.

Vaxcyte

Market Cap: US$8.2b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

ImmunityBio

Market Cap: US$8.1b

A biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases.

Oruka Therapeutics

Market Cap: US$5.2b

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Veradermics

Market Cap: US$5.2b

A clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.

CRISPR Therapeutics

Market Cap: US$5.1b

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.

Caris Life Sciences

Market Cap: US$4.9b

An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.

Celcuity

Market Cap: US$4.5b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Legend Biotech

Market Cap: US$4.5b

Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.

Viking Therapeutics

Market Cap: US$4.4b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Tango Therapeutics

Market Cap: US$4.4b

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

Dyne Therapeutics

Market Cap: US$4.0b

A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.

NewAmsterdam Pharma

Market Cap: US$3.7b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Denali Therapeutics

Market Cap: US$3.7b

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

Structure Therapeutics

Market Cap: US$3.5b

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.

Ultragenyx Pharmaceutical

Market Cap: US$3.1b

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

Beam Therapeutics

Market Cap: US$3.1b

A biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.

Vera Therapeutics

Market Cap: US$3.1b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

Celldex Therapeutics

Market Cap: US$3.0b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

uniQure

Market Cap: US$2.8b

Develops treatments for patients suffering from rare and other devastating diseases in the United States.

Kodiak Sciences

Market Cap: US$2.6b

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Immunome

Market Cap: US$2.6b

A biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.

SELLAS Life Sciences Group

Market Cap: US$2.5b

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.

Kailera Therapeutics

Market Cap: US$2.5b

Operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.

Tarsus Pharmaceuticals

Market Cap: US$2.5b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

Mineralys Therapeutics

Market Cap: US$2.4b

A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.

BioCryst Pharmaceuticals

Market Cap: US$2.4b

A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Nektar Therapeutics

Market Cap: US$2.3b

A biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

Zai Lab

Market Cap: US$2.3b

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.

Biohaven

Market Cap: US$2.2b

A biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

Ocular Therapeutix

Market Cap: US$2.2b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

Palvella Therapeutics

Market Cap: US$2.2b

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.